Abstract: A method for treating inclusion body myositis (IBM) in a subject can include: providing a subject that has IBM; obtaining adipose-derived regenerative cells (ADRC); and administering the ADRC to the subject to treat the IBM. The ADRCs can be obtained by a closed system for use as the therapeutic as described herein. The ADRCs can be obtained in a system that can then be used for providing the ADRCs for administration. The system can be automated and may provide the ADRCs in sufficient purity for reimplantation. The method can include: injecting the ADRC as cells into one injection location or a plurality of injection locations to provide at least a million cells, more preferably at least 10 million cells, even more preferably at least 20 million cells, or most preferably at least 30 million cells.

Abstract: Embodiments of the present disclosure relate generally to the production of therapeutic mesenchymal stem cells (MSCs). More particularly, the present disclosure relates to the use of cell culture compositions and methods for generating MSCs that secrete neurotrophic factors and synaptic organizing agents for the treatment of neurodegenerative diseases such as Amyotrophic Lateral Sclerosis (ALS). As such, the present disclosure addresses the need for establishing a reliable source of therapeutic stem cells useful for the treatment of neurodegenerative diseases.

Abstract: Embodiments of the present disclosure relate generally to the production of therapeutic mesenchymal stem cells (MSCs). More particularly, the present disclosure relates to the use of cell culture compositions and methods for generating MSCs that secrete neurotrophic factors and synaptic organizing agents for the treatment of neurodegenerative diseases such as Amyotrophic Lateral Sclerosis (ALS). As such, the present disclosure addresses the need for establishing a reliable source of therapeutic stem cells useful for the treatment of neurodegenerative diseases.

Abstract: Embodiments of the present disclosure relate generally to the production of therapeutic mesenchymal stem cells (MSCs). More particularly, the present disclosure relates to the use of cell culture compositions and methods for generating MSCs that secrete neurotrophic factors and synaptic organizing agents for the treatment of neurodegenerative diseases such as Amyotrophic Lateral Sclerosis (ALS). As such, the present disclosure addresses the need for establishing a reliable source of therapeutic stem cells useful for the treatment of neurodegenerative diseases.